Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
News|Poll|March 28, 2014
Tongue Spots
This lesion, present for 4 months, had not responded to oral nystatin or fluconazole. Multiple, nontender, whitish, vertical striations were noted along its right lateral edge. Your dx?
Advertisement
This lesion, present for 4 months, had not responded to oral nystatin or fluconazole. Multiple, nontender, whitish, vertical striations were noted along its right lateral edge. The patient had a 15 packyear smoking history.
Your dx?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5